INTRODUCTION
Since March 2014, West Africa has experienced the largest outbreak of Ebola in history, with multiple countries affected and with more than 25,000 people infected and more than 12,000 deaths (1) . Lack of vaccine and drugs for prevention and treatment of the Ebola hemorrhagic fever clearly demonstrated that the world was not prepared for an outbreak of this nature. A new outbreak of Ebola in Congo shows that three years later the situation is not completely under control. Despite recent headlines and scientific articles declaring the success of an experimental Ebola vaccine and drugs, the world still is not prepared for future Ebola epidemics and is not in position to prevent another deadly outbreak due to limited therapeutic and /or prophylactic options.
From the point of view of drug development, this was expected. Development of drugs is an expensive and time-consuming process, which takes more than ten years and costs more than US$ 2 billion (2). Drug development is also risky because the estimated final success rates at which new drugs receive approval from regulatory agencies is less than 35% (3).
Drug repositioning (also referred to as drug repurposing, re-profiling, therapeutic switching and drug re-tasking), is the identification of new therapeutic indications for known drugs. One motivation behind drug repositioning is the treatment of rare or neglected diseases as limited drug development exists in this field. Therefore, testing of safe and active molecules already developed for other indications, deemed suitable and attractive for this purpose.
Repurposing of approved drugs for the treatment of Ebola disease
In response to the Ebola virus outbreak in West Africa 2015, drug repositioning was considered as a possible short-cut to Ebola drugs, because conventional time and money consuming approach of drug development (> 10 years; > 2 billion $) does not meet urgent need for these therapeutics. Although this approach does not remove the need for certain preclinical and clinical studies, it is promising in terms of acceleration of discovery of urgently needed drugs for the treatment of Ebola disease.
The first large repurposing screening of the Food and Drug Administration (FDA)-approved drugs has been reported in 2013 . In this study, Madrid and co-workers performed in vitro and in vivo screening of 1012 FDA-approved drugs and selected 24 candidate entry inhibitors for Ebola virus (4) . The most noteworthy antiviral compound identified was chloroquine, which disrupted entry and replication of the virus in vitro and protected mice against Ebola virus challenge in vivo.
In the second large study, 53 inhibitors of Ebola virus infection with IC 50 <10 µM and selectivity index SI >10-fold have been identified by in vitro screening of 2816 FDA-approved drugs (5). These 53 active compounds were divided into different functional categories including microtubule inhibitors, estrogen receptor modulators, antihistamines, antipsychotics, pump/channel antagonists, and anticancer/antibiotics. In the same study, additional 95 drugs active against Ebola virus infection with IC 50 > 10 µM and SI <10-fold were also reported (5).
The criterion for in silico screening of molecular libraries for candidate Ebola drugs, which is based on the electron-ion interaction potential (EIIP) and the average quasi-valence number (AQVN), was proposed (6). These molecular descriptors determine specific recognition and targeting between interacting biological molecules at distances >5 Å (7). Analysis of the 152 small molecule inhibitors of Ebola virus infection, selected by in vitro screening of 3828 FDA approved drugs (6) , show that 79% of these compounds are placed within AQVN and EIIP regions (2.3. -2.7.) and (0.0.829 -0.0.954 Ry), respectively. This part of the AQVN/EIIP space was designed as the "Ebola Virus Infection Inhibitors Space" (EVIIS). The AQVN region (2.3.6 -2.5.4) and the EIIP region (0.0.912 -0.0.924 Ry) form the part of EVIIS, which encompasses 55.5. % of all drugs from the learning set (core EVIIS, cEVIIS). Additional literature data mining revealed 49 compounds with experimentally proved activity against Ebola virus infection and most of these compounds 47 (95.9. %) were placed within EVIIS. By repurposing virtual screening of 6438 drugs from DrugBank (http:// www.drugbank.ca) using EVIIS as a filter, 267 approved and 382 experimental drugs have been selected as candidates for the treatment of Ebola virus disease, including 15 anti-malarial drugs and 32 antibiotics, (6) .
Recently, several studies in silico, in vitro and in vivo were carried out for repurposing of approved drugs for prevention and treatment of the Ebola disease (8) . The AQVN and EIIP values calculated for drugs selected in these studies are given in Table 1 . Sixty eight percent of these drugs are located within the EVIIS domain of the AQVN/EIIP space and we selected previously the majority of them as candidate Ebola drugs (6) . These results additionally confirm efficacy of the proposed AQVN/EIIP filter for in silico screening of the molecular libraries for candidate Ebola drugs.
By detailed analysis of approved drugs located within EVIIS, including the docking analysis, we selected the non-steroidal anti-inflammatory drug ibuprofen as an inexpensive, widely accessible and minimally toxic candidate for prevention and treatment of Ebola virus disease (9) . Later high resolution structural study confirmed binding of ibuprofen to the Ebola virus glycoprotein (GP) (10) . Authors of this study hypothesized that ibuprofen binding destabilizes GP and triggers premature release of the subunit GP2 of this protein, thereby preventing fusion between the viral and endosome membranes (10) .
The binding site of ibuprofen on the Ebola virus GP proposed by Zhao and co-workers (10) differs from the binding site proposed in our study (9) . In this article, we performed an additional docking analysis in order to explain possible reason for this discrepancy. We also experimentally confirmed inhibitory effect of ibuprofen on the Ebola virus. In Zhao's paper, authors used EBOV GP pseudotyped HIV virus as a surrogate to study the effect of drugs on EBOV infectivity. We used EBOV in our study.
These results, together with the results reported by Zhao and co-workers, suggest ibuprofen as the molecular template for development of drugs for treatment of the Ebola virus disease.
MATERIAL AND METHODS

Ligand optimization
Ligands were built in VEGAZZ (11), protonated according to physiological conditions and optimized on PM6 level of theory using MOPAC 2009.
Molecular docking
Ligand and receptor were prepared using AutoDock Tools 1.5.7. (12). The docking was carried with Autodock Vina1.1.2. (13). The whole receptor conformational space was searched, using grid box dimensions 60 × 60 × 60 Å3. After selection of conformations that were docked near recognized sequences important for binding of anti-malarials, the binding pocket was recognized, grid box centerd to occupy close amino acid residues and set to dimensions Based on (7) (8) (9) (10) (11) (12) of 20 × 20 × 20 Å3. The docking was carried out with and without weighting of hydrophilic interactions. In case of hydrophilic weighting, the value was set to -1.2.0 (compared to default weight_hydrogen = -0.5.87439 value). The exhaustiveness was set to 250. For the rescoring process of ibuprofen crystalyzed with Ebola glycoprotein, GP structures and ibuprofen coordinates were taken from pdb structure 5JQB, and all other rescoring parameters were set to be the same as in the docking process to our GP1 model.
Inhibition of Ebola virus with ibuprofen
We incubated the virus with 100 uM ibuprofen and performed plaque assay after diluting the virus with media containing ibuprofen. Briefly, we incubated either 20 or 4 µl of Ebola (Zaire) virus (containing 1.3.6x10^5 PFU or 0.2.7x10^5 PFU virus respectively) with 180 µl of DMEM+2% FBS containing 100 uM ibuprofen in a 96-well plate in triplicates. As control, we incubated 20 µl of Ebola virus (1.3.6x10^5 PFU) or 4 µl virus (0.2.7 x10^5 PFU) with 180 µl of DMEM+2% FBS containing 0.5.% DMSO in a 96-well plate in triplicates. Samples are than diluted 1:10 in corresponding media for 4 times. After that we infected Vero cells grown on 12-well plates with 100 µl of above diluted samples for 1 hr with shaking performed for every 15 mins. Upon incubation time, we perform plaque assay in which we fixed the cells and counted plaques at 11 dpi.
RESULTS AND DISCUSSION
Rescoring the position of the ibuprofen molecule in pdb structure 5jqb yielded binding energy value of -5.8.2 kcal/mol. Comparing to our previous results, which gave binding energy value of -9.0. kcal/ mol in our predicted region, it is significantly weaker, but again, closer to the experimentally determined Kd of 6 mM (-5.8.2 kcal/mol corresponds to Kd=78μM). This can be explained as a matter of protein-ligand interactions type between interacting atoms of amino acid residues and the ibuprofen molecule. In the case of the crystal structure 5jqb, ibuprofen is placed in the fusion region between GP1 and GP2 subunits, forming interactions with Arg64 (salt bridge), Val66 and Leu184 from GP1 and Met548 and Leu554 from GP2 (hydrophobic interactions) (10) . The binding region is far from the one we previously predicted, and still not crystalographically isolated (9) . Also, our homology modelling of GP1 suggested disordered structure of the binding region (Figure 1 ). The reported intermolecular interactions from docking were with Thr 338, Ser 340, Gln 344 (hydrophilic interactions) and with Ala415 (hydrophobic interactions) (9) . Therefore, binding of ibuprofen to this region is favoured by more hydrophilic interactions and a disordered structure that could be more prone to finer structural tuning of the binding site to ibuprofen than the one in the 5jqb structure suggested by Zhao and co-workers (10). However, binding energy calculations are limited by the docking software forcefield. Structural data reported by Zhang and co-workers indicate that the GP fusion is hindered by ibuprofen binding to fusion regions (10) . Our results suggest that binding of ibuprofen to GP1 modulates the long-range interaction between virus and the receptor. This does not exclude the possible existence of two different binding sites for ibuprofen on the Ebola GP, which modulates virus/host interaction in different ways.
The experiments with infectious Ebola virus have shown that 100 µM ibuprofen can reduce the virus titer in Vero cells by 50% (Table 2) , however, the biological significance of this reduction is not established yet.
In conclusion, results presented here, together with data reported by Zhao and co-workers (10), suggest that ibuprofen, although a weak inhibitor of the Ebola virus infection, represents a promising molecular template for further development of drugs against this important pathogen. Crystal structure of GP1 (green) and GP2 (red) subunits with ibuprofen molecule (CPK presentation), from pdb structure 5jqb, overlayed with our GP1 model (blue). Yellow region on GP1 model is not crystalized and is considered disordered. 
